Some researchers report that microdosing at 1.0mg to 1.25mg weekly produces meaningful appetite suppression with virtually no gastrointestinal side effects
Common mistakes: Removing pens from their outer carton before use Storing vials on a countertop or windowsill Using clear travel cases without UV protection Keep semaglutide in its original packaging until you are ready to inject
Access to GLP-1 agonists, including Victoza and Ozempic, may also be an issue for some individuals
Cardiovascular outcomes data are still being collected as part of ongoing trials
With few exceptions (e.g., anti-amyloid antibodies), most are still in early phases of clinical research and efficacy data from large phase 3 or 4 clinical trials are not yet available
Heinis, C., Rutherford, T., Freund, S